MEDFORD, N.Y.--(BUSINESS WIRE)--Chembio Diagnostics, Inc. (OTCBB:CEMI) has signed a Cooperative Research and Development Agreement (CRADA) with the United States Centers for Disease Control and Prevention (CDC) to develop a rapid combination test for syphilis utilizing Chembio’s Dual Path Platform (DPP™) technology and the CDC’s patented Syphilis antigens. The test is being designed to detect both treponemal and nontreponemal antibodies in the same device and therefore could potentially be both a screening and confirmatory test in a point of care setting.
